Cyclic ADP-ribose contributes to contraction and Ca2+ release by M1 muscarinic receptor activation in coronary arterial smooth muscle

J Vasc Res. 2003 Jan-Feb;40(1):28-36. doi: 10.1159/000068936.

Abstract

The present study determined the role of cyclic ADP-ribose (cADPR) in mediating vasoconstriction and Ca(2+) release in response to the activation of muscarinic receptors. Endothelium-denuded small bovine coronary arteries were microperfused under transmural pressure of 60 mm Hg. Both acetylcholine (ACh; 1 nmol/L to 1 micromol/L) and oxotremorine (OXO; 2.5-80 micromol/L) produced a concentration-dependent contraction. The vasoconstrictor responses to both ACh and OXO were significantly attenuated by nicotinamide (Nicot; an ADP-ribosyl cyclase inhibitor), 8-bromo-cADPR (8-Br-cADPR; a cADPR antagonist) or ryanodine (Ry; an Ry receptor antagonist). Intracellular Ca(2+) ([Ca(2+)](i)) was determined by fluorescence spectrometry using fura-2 as a fluorescence indicator. OXO produced a rapid increase in [Ca(2+)](i) in freshly isolated single coronary arterial smooth muscle cells (CASMCs) bathed with Ca(2+)-free Hanks' solution. This OXO-induced rise in [Ca(2+)](i) was significantly reduced by pirenzepine (PIR; an M(1) receptor-specific blocker), Nicot, 8-Br-cADPR or Ry. The effects of OXO on the activity of ADP-ribosyl cyclase (cADPR synthase) were examined in cultured CASMCs by measuring the rate of cyclic GDP- ribose (cGDPR) formation from beta-nicotinamide guanine dinucleotide. It was found that OXO produced a concentration-dependent increase in the production of cGDPR. The stimulatory effect of OXO on ADP-ribosyl cyclase was inhibited by both PIR and Nicot. These results suggest that the cADPR signaling pathway participates in the contraction of small coronary arterial smooth muscle and Ca(2+) release induced by activation of M(1) muscarinic receptors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • ADP-ribosyl Cyclase / antagonists & inhibitors
  • Acetylcholine / pharmacology
  • Animals
  • Calcium / metabolism*
  • Calcium Channels
  • Cattle
  • Coronary Vessels / physiology*
  • Cyclic ADP-Ribose / physiology*
  • Endothelium, Vascular / physiology
  • Enzyme Inhibitors / pharmacology
  • Fluorescent Dyes
  • Fura-2
  • Inositol 1,4,5-Trisphosphate Receptors
  • Muscarinic Agonists / pharmacology
  • Muscle Contraction* / drug effects
  • Muscle, Smooth, Vascular / physiology*
  • Niacinamide / pharmacology
  • Oxotremorine / pharmacology
  • Receptor, Muscarinic M1
  • Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors
  • Receptors, Muscarinic / physiology*
  • Ryanodine / pharmacology
  • Ryanodine Receptor Calcium Release Channel / drug effects
  • Spectrometry, Fluorescence
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology
  • Vasodilator Agents / pharmacology

Substances

  • Calcium Channels
  • Enzyme Inhibitors
  • Fluorescent Dyes
  • Inositol 1,4,5-Trisphosphate Receptors
  • Muscarinic Agonists
  • Receptor, Muscarinic M1
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Muscarinic
  • Ryanodine Receptor Calcium Release Channel
  • Vasodilator Agents
  • Cyclic ADP-Ribose
  • Ryanodine
  • Niacinamide
  • Oxotremorine
  • ADP-ribosyl Cyclase
  • Acetylcholine
  • Calcium
  • Fura-2